Latest Milan News

Lendlease and Bizzi & Partners have extended the deadline for conditions attached to the proposed sale of Lendlease’s MSG North development rights in Milan. Closing remains uncertain, with Lendlease warning it may need to fund approximately $160 million of project obligations if the transaction fails.

CZR Resources has expanded gold mineralisation at its Croydon Gold Project in the Pilbara, with drilling at Top Camp and Bottom Camp revealing significant strike extensions and high-grade intercepts. Early results from the Martin prospect highlight promising pathfinder elements, setting the stage for further exploration.

CZR Resources has launched a recommended takeover bid for Zuleika Gold, backed by a robust $65 million cash position and promising drilling results at its Croydon Gold Project.

CZR Resources has reported new drilling results from its Croydon Gold Project, revealing high-grade gold intercepts and extending mineralisation to over 700m strike and 220m depth.

Investigator Silver has moved the Paris Silver Project decisively from study to execution, bolstered by a strong cash position and key executive hires to drive development and financing.

CZR Resources (ASX:CZR) has launched a recommended all-scrip takeover bid for Zuleika Gold (ASX:ZAG), valuing the company at $44.8 million and offering a significant premium to Zuleika shareholders.

Lendlease is selling its 25.1% stake in the Keyton Retirement Living Trust to Aware Super for $525 million, part of a broader $3.4 billion capital recycling push aimed at debt reduction.

Lendlease is advancing its capital recycling strategy by selling the development rights to its Milano Santa Giulia North project in Milan for approximately $250 million, anticipating a significant operating loss in FY26.

CZR Resources shakes up leadership with Managing Director Stefan Murphy's exit and Milan Jerkovic stepping in as Acting CEO, accompanied by the appointment of Alex Neuling as an independent director.

Vmoto Limited reports a robust sales rebound in the final quarter of 2025, with a 68% jump in units sold and a near doubling of firm orders, underpinned by strategic partnerships and expanding manufacturing capacity.

OncoSil Medical has reported a record quarter for dose sales alongside key European market entries and a successful manufacturing milestone, signalling growing momentum for its pancreatic cancer treatment.

OncoSil Medical’s interim OSPREY registry data reveals promising survival improvements for patients with unresectable locally advanced pancreatic cancer treated with OncoSil™ plus chemotherapy. The findings suggest a meaningful step forward in a field with limited effective options.